AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Creative Medical Technolo... (CELZ)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.92

-0.23 (-3.74%)

At close: Feb 20, 2025, 3:59 PM

6.15

3.89%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	5.5
Market Cap	10.35M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.8
PE Ratio (ttm)	-1.56
Forward PE	n/a
Analyst	n/a

Ask	6.8
Volume	333,325
Avg. Volume (20D)	58,645
Open	6.68
Previous Close	6.15
Day's Range	5.55 - 6.90
52-Week Range	1.96 - 10.28
Beta	undefined

About CELZ

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Te...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 6, 2015

Employees 4

Stock Exchange NASDAQ

Ticker Symbol CELZ

Website https://www.creativemedicaltechnology.com

Full Company Profile

Why Price Moved

6 days ago

+3.27%

Creative Medical Technology Holdings shares are tr... Unlock content with Pro Subscription

4 months ago

-22.57%

Creative Medical Technology shares are trading lower. The company announced a $1.85 million registered direct offering priced at the market under Nasdaq rules.

News

11 months ago · businesswire.com

Creative Medical Technology Holdings Provides Corporate Update

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to imm...

11 months ago · zacks.com

Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101

Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.

11 months ago · businesswire.com

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The com...

11 months ago · businesswire.com

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocri...

1 year ago · prismmediawire.com

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

New York, December 21, 2023 – Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company's innovative StemSpine® treat...